Your browser doesn't support javascript.
Organoid and microfluidics-based platforms for drug screening in COVID-19.
Ramezankhani, Roya; Solhi, Roya; Chai, Yoke Chin; Vosough, Massoud; Verfaillie, Catherine.
  • Ramezankhani R; Department of Applied Cell Sciences, Faculty of Basic Science and Advanced Medical Technologies, Royan Institute, ACECR, Tehran, Iran; Department of Development and Regeneration, Stem Cell Biology and Embryology, KU Leuven Stem Cell Institute, Leuven, Belgium; Department of Regenerative Medicine, Ce
  • Solhi R; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Education, Culture and Research, ACECR, Tehran, Iran; Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Ira
  • Chai YC; Department of Development and Regeneration, Stem Cell Biology and Embryology, KU Leuven Stem Cell Institute, Leuven, Belgium.
  • Vosough M; Department of Applied Cell Sciences, Faculty of Basic Science and Advanced Medical Technologies, Royan Institute, ACECR, Tehran, Iran; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Academic Center for Education, Culture and R
  • Verfaillie C; Department of Development and Regeneration, Stem Cell Biology and Embryology, KU Leuven Stem Cell Institute, Leuven, Belgium. Electronic address: Catherine.verfaillie@kuleuven.be.
Drug Discov Today ; 27(4): 1062-1076, 2022 04.
Article in English | MEDLINE | ID: covidwho-1587950
ABSTRACT
Proposing efficient prophylactic and therapeutic strategies for coronavirus 2019 (COVID-19) requires precise knowledge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis. An array of platforms, including organoids and microfluidic devices, have provided a basis for studies of SARS-CoV-2. Here, we summarize available models as well as novel drug screening approaches, from simple to more advanced platforms. Notably, organoids and microfluidic devices offer promising perspectives for the clinical translation of basic science, such as screening therapeutics candidates. Overall, modifying these advanced micro and macro 3D platforms for disease modeling and combining them with recent advances in drug screening has significant potential for the discovery of novel potent drugs against COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Organoids / Microfluidics / Drug Evaluation, Preclinical / SARS-CoV-2 / COVID-19 Drug Treatment / Models, Biological Type of study: Prognostic study Topics: Traditional medicine Limits: Animals / Humans Language: English Journal: Drug Discov Today Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Organoids / Microfluidics / Drug Evaluation, Preclinical / SARS-CoV-2 / COVID-19 Drug Treatment / Models, Biological Type of study: Prognostic study Topics: Traditional medicine Limits: Animals / Humans Language: English Journal: Drug Discov Today Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article